EHP Funds Inc. Grows Position in Bristol-Myers Squibb (NYSE:BMY)

EHP Funds Inc. grew its stake in Bristol-Myers Squibb (NYSE:BMY) by 7.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,000 shares of the biopharmaceutical company’s stock after purchasing an additional 400 shares during the period. EHP Funds Inc.’s holdings in Bristol-Myers Squibb were worth $308,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Northwest Financial Advisors purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $27,000. Pacific Capital Wealth Advisors Inc. purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $34,000. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $40,000. Wetzel Investment Advisors Inc. purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $40,000. Finally, VisionPoint Advisory Group LLC lifted its position in shares of Bristol-Myers Squibb by 300.5% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 553 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. BMO Capital Markets decreased their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Barclays decreased their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 23rd. Finally, William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $60.00.

Bristol-Myers Squibb Stock Up 1.5 %

Shares of BMY traded up $0.60 during midday trading on Friday, hitting $41.48. The company had a trading volume of 13,665,456 shares, compared to its average volume of 14,074,232. The company’s 50-day simple moving average is $45.50 and its 200-day simple moving average is $48.98. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The firm has a market capitalization of $84.08 billion, a P/E ratio of -13.38, a P/E/G ratio of 14.04 and a beta of 0.43. Bristol-Myers Squibb has a 1 year low of $39.91 and a 1 year high of $66.38.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the business posted $2.05 EPS. As a group, sell-side analysts expect that Bristol-Myers Squibb will post 0.59 EPS for the current year.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.